Planned sales, announced before they happen
2 trading plans running, 7 Form 144 notices for $14.7M
Plans running now
2
Geoff Martha, Michael Marinaro
What MDT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans
Plans adopted or ended
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Geoff Martha Chairman and Chief Executive Officer |
Adopted 10b5-1 plan | Jul 16, 2026 | up to 50,000 | Nov 30, 2026 | 10-Q Sep 3, 2026 |
What the company wroteOn July 16, 2026, Geoff Martha, Chairman and Chief Executive Officer, adopted a Rule 10b5-1 trading plan. The trading plan provides for the sale of up to 50,000 shares of the Company’s common stock starting as early as October 15, 2026, prior to the plan's termination date of November 30, 2026. | |||||
| Matthew Walter Senior Vice President, Human Resources, IT, and Global Communications & Corporate Marketing |
Adopted 10b5-1 plan | Feb 27, 2026 | up to 3,102 | Jul 10, 2026 | 10-K Jun 18, 2026 |
What the company wroteOn February 27, 2026, Matthew Walter, Senior Vice President, Human Resources, IT, and Global Communications & Corporate Marketing, adopted a Rule 10b5-1 trading plan. Subsequently, on April 7, 2026, Mr. Walter amended the trading plan's starting and termination date. The trading plan provides for the sale of up to 3,102 shares of the Company’s common stock starting as early as July 8, 2026, prior to the plan's July 10, 2026, termination date. | |||||
| Michael Marinaro Executive Vice President |
Adopted 10b5-1 plan | Feb 19, 2026 | up to 10,420 | Dec 15, 2026 | 10-K Jun 18, 2026 |
What the company wroteOn February 19, 2026, Michael Marinaro, Executive Vice President and President Medical Surgical Portfolio, Americas, and Global Commercial Operations, adopted a Rule 10b5-1 trading plan. Subsequently, on March 17, 2026, Mr. Marinaro amended the trading plan's starting and termination date and to provide a limit price for sales subject to the plan. The trading plan provides for the sale of up to 10,420 shares of the Company’s common stock starting as early as June 15, 2026, prior to the plan's December 15, 2026, termination date. | |||||
| Brett Wall Executive Vice President and President |
Adopted 10b5-1 plan | Oct 10, 2024 | up to 22,287 | Aug 1, 2025 | 10-Q Nov 26, 2024 |
What the company wroteOn October 10, 2024, Brett Wall, Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan. Mr. Wall's trading plan provides for the sale of up to 22,287 shares of the Company's common stock prior to the plan's August 1, 2025 termination date. | |||||
| Brett Wall Executive Vice President and President Neuroscience Portfolio |
Adopted other arrangement | Sep 20, 2023 | up to 4,997 | 93 days | 10-Q Nov 30, 2023 |
What the company wroteOn September 20, 2023, Brett Wall, Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan. Mr. Wall’s trading plan provides for the sale of 4,997 shares of the Company’s common stock at market on December 19, 2023 prior to the plan's December 22, 2023 termination date. | |||||
| Karen L. Parkhill Executive Vice President and Chief Financial Officer |
Adopted plan | Jul 14, 2023 | up to 3,351 | – | 10-Q Aug 31, 2023 |
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 14 filings checked since Jun 22, 2023.
Form 144
Notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Marinaro Michael Officer |
10,420 | $1.0M | Dividend Reinvestment; ESPP Purchase; Restricted Stock Vesting; Stock Option Exercise | adopted Mar 17, 2026 | 10,420 shares from Oct 15, 2026 |
| Oct 15, 2026 | Martha Geoffrey Officer, Director |
50,000 | $4.8M | Restricted Stock Vesting; Stock Option Exercise | adopted Jul 16, 2026 | 50,000 shares from Oct 15, 2026 |
| Sep 16, 2026 | KIIL HARRY SKIP Officer |
1,483 | $139K | Restricted Stock Vesting | none given | 1,483 shares from Sep 16, 2026 |
| Jul 8, 2026 | Walter Matthew R. Officer |
3,102 | $258K | Dividend Reinvestment; ESPP Purchase; Restricted Stock Vesting | adopted Apr 7, 2026 | 3,102 shares from Jul 8, 2026 |
| Jun 8, 2026 | KIIL HARRY SKIP Officer |
4,189 | $337K | Restricted Stock Vesting | none given | 4,189 shares from Jun 8, 2026 |
| Feb 19, 2026 | KIIL HARRY SKIP Officer |
52,524 | $5.1M | Option Granted 07/29/2024; Option Granted 07/31/2023; Option Granted 08/01/2022; Restricted Stock Vesting | none given | none found |
| Nov 19, 2025 | Smith Gregory L Officer |
30,000 | $3.1M | ESPP Purchase; Restricted Stock Vesting | none given | none found |
From the Form 144 XML filed with the SEC, since Nov 19, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.